- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04717700
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (SABLe)
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe): An Investigator Sponsored Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
An unrandomized phase 2 study evaluating selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly diagnosed transplant in-eligible symptomatic multiple myeloma patients in a multicenter international set-up with in the Nordic Multiple Myeloma Study Group.
The study will include 50 patients, recruited within the NMSG collaborating countries. After induction patient will be treated with continued lenalidomide-dexamethasone according to SWOG, with continuous 40mg selinexor weekly in the selinexor arm (experimental arm B).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ida B Kristensen, MD
- Phone Number: +4565411152
- Email: ida.bruun.kristensen@rsyd.dk
Study Locations
-
-
-
Aalborg, Denmark
- Aalborg University Hospital
-
Esbjerg, Denmark
- Sydvestjysk Sygehus Esbjerg
-
Gødstrup, Denmark
- Regionshospitalet Gødstrup
-
Odense, Denmark
- Odense University Hospital
-
-
-
-
-
Tallinn, Estonia, 13419
- North Estonia Medical Centre Foundation
-
-
-
-
-
Bergen, Norway
- Haukeland University Hospital
-
Førde, Norway
- Førde Central Hospital
-
Kristiansund, Norway
- Kristiansund Hospital
-
Oslo, Norway
- Oslo Universitets Hospital
-
Stavanger, Norway
- Stavanger University Hospital
-
Trondheim, Norway
- St. Olavs University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible to enroll in this study:
- Age > 18 years
- Willing and able to provide written informed consent in accordance with national, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of ≤ 2. ECOG 3 allowed if caused by myeloma
- Newly diagnosed multiple myeloma with treatment demanding disease as defined by IMWG (Rajkumar, Dimopoulos et al. 2014) and measurable disease as defined IMWG 2016 criteria (Table 5) (Kumar, Paiva et al. 2016)
- By treating physician considered in-eligible for high-dose therapy with stem-cell transplant
- Patients must have received no prior chemotherapy for multiple myeloma. Patients must have received no prior radiotherapy to a large area of the pelvis (more than half of the pelvis). Patients must have received no prior steroid treatment for myeloma with the exception of a maximum of 14 days of treatment for symptom control (including dexamethasone 40mg).
Adequate hepatic function within 7 days prior to C1D1:
- Total bilirubin < 1.5 × upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of < 3 × ULN), and
- Alanine aminotransferase (ALT) normal to <2 × ULN.
Adequate renal function within 7 days prior to C1D1 as determined by estimated GFR of ≥ 30 mL/min, calculated using standard formula.
- Adequate hematopoietic function within 7 days prior to C1D1: Absolute neutrophil count ≥1000/mm3, and platelet count ≥100,000/mm3 (patients for whom <50% of bone marrow nucleated cells are plasma cells). If cytopenias are due a plasma cell infiltration in the bone marrow (biopsy-proven heavy-marrow involvement, as defined by having at least 30% marrow cellularity, with > 50% of the cells being malignant plasma cells (documented marrow results required)); in this case, although there are no required lower limits of normal for the blood counts, the treating physician must use his/her medical judgment as to the appropriateness of this study therapy for these patients.
- Erythropoietin-analogues are allowed.
Patients must have:
- At least a 1-week interval from the last platelet transfusion prior to the screening platelet assessment.
However, patients may receive RBC and/or platelet transfusions as clinically indicated per institutional guidelines during the study.
- Female patients of childbearing potential must have a negative serum pregnancy test at Screening. Female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 3 months following the last dose of study treatment.
- Patients must be able to take prophylactic anticoagulation as recommended by study
- Patients with pathologic fractures, infection at diagnosis or symptomatic hyperviscosity must have these conditions attended to prior to registration (i.e., intramedullary rod, I.V. antibiotics, plasmapheresis)
Exclusion Criteria:
Exclusion Criteria:
Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:
- Has received selinexor or another XPO1 inhibitor previously.
- Has any concurrent medical condition or disease (eg, uncontrolled active hypertension, uncontrolled active diabetes, active systemic infection, etc.) that is likely to interfere with study procedures.
- Known intolerance, hypersensitivity, or contraindication to glucocorticoids, bortezomib, lenalidomide and selinexor.
- Pregnant or breastfeeding females.
- Life expectancy of less than 6 months.
Active, unstable cardiovascular function, as indicated by the presence of:
- Symptomatic ischemia, or
- Uncontrolled clinically significant conduction abnormalities (eg, patients with ventricular tachycardia on anti-arrhythmics are excluded; patients with first degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block will not be excluded), or
- Congestive heart failure of New York Heart Association Class ≥3 or known left ventricular ejection fraction <40%, or
- Myocardial infarction within 6 months prior to C1D1.
- Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.
- Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).
- Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.
- Contraindication to any of the required concomitant drugs or supportive treatments.
- Patients unwilling or unable to comply with the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: B -selinexor-lenalidomide/bortezomib-dexamethasone
Alternating cycles of: Selinexor oral 40mg once weekly Lenalidomide oral 25mg d 1-21 Dexamethasone 20mg d 1+2, 8+9 and 15+16 i 28 days cycles and Selinexor oral 80mg once weekly Bortezomib sc 1.3mg/sqm once weekly Dexamethasone 20mg d 1+2, 8+9 and 15+16 in 28 days cycles for up to 16 cycles (8 of each, alternating) followed by continuos selinexor 40mg(once weekly)-lenalidomide-dexamethasone for up to 16 cycles followed by continuos lenalidomide-dexamethasone |
Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
Other Names:
Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
Other Names:
Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
Other Names:
Comparing an alternating regimen of selinexor-lenalidomide/bortezomib-dexamethasone to standard bortezomib-lenalidomide-dexamethasone
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increased ORR in arm B (defined as ≥PR) at end of induction, defined according to IMWG response criteria
Time Frame: Estimated at 4-8 weeks after end of induction
|
ORR at end of induction, with response defined according to IMWG response criteria
|
Estimated at 4-8 weeks after end of induction
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increased VGPR rate at end of induction in arm B
Time Frame: Estimated at 4-8 weeks after end of induction
|
VGPR rate at end of induction
|
Estimated at 4-8 weeks after end of induction
|
Increased rate of MRD negativity at end of induction in arm B
Time Frame: Estimated at 4-8 weeks after end of induction
|
MRD negativity by NGS at end of induction
|
Estimated at 4-8 weeks after end of induction
|
Decreased time to response in arm B
Time Frame: Estimated monthly during the first 64 weeks
|
Time to at least PR from start of treatment
|
Estimated monthly during the first 64 weeks
|
Evaluate toxicity rates between arm A and B, including rates of secondary primary malignancies
Time Frame: Estimated at 4-8 weeks after end of induction
|
Comparison of toxicity rates according to NCI-CTCAE v4.03
|
Estimated at 4-8 weeks after end of induction
|
Decreased time to at least VGPR
Time Frame: Estimated monthly during the first 64 weeks
|
Time to at least VGPR from start of treatment
|
Estimated monthly during the first 64 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ida B Kristensen, MB, Odense University Hospital
- Principal Investigator: Hanne Norseth, MD, Oslo University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Lenalidomide
- Bortezomib
Other Study ID Numbers
- NMSG 29/21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Bortezomib Injection
-
AHS Cancer Control AlbertaTom Baker Cancer CentreRecruitingMyeloma | Myeloma MultipleCanada
-
Millennium Pharmaceuticals, Inc.CompletedMantle Cell LymphomaUnited States
-
Millennium Pharmaceuticals, Inc.CompletedProstatic NeoplasmsUnited States
-
Millennium Pharmaceuticals, Inc.TerminatedAdvanced Non-Small Cell Lung Cancer | Other Solid Tumors
-
Millennium Pharmaceuticals, Inc.CompletedNon-Small Cell Lung CancerUnited States
-
Millennium Pharmaceuticals, Inc.CompletedColorectal CarcinomaUnited States
-
Peking Union Medical College HospitalCompletedAutoimmune Hemolytic Anemia | Autoimmune Hemolytic Anemia and Autoimmune ThrombocytopeniaChina
-
Chinese University of Hong KongShanghai Children's Medical CenterCompletedAcute Lymphoblastic Leukemia, in RelapseHong Kong
-
Peking Union Medical College HospitalNot yet recruitingThrombotic Thrombocytopenic Purpura, AcquiredChina
-
Millennium Pharmaceuticals, Inc.Johnson & Johnson Pharmaceutical Research & Development, L.L.C.CompletedA Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple MyelomaMultiple MyelomaBelgium, France, Germany